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Abstract 
Aim: The aim of our study was to systematically review the literature on temporal 
Bayesian networks and its relation with clinical outcomes. 
Background: Medical knowledge is growing at a fiery rate. While the obtainability of 
pertinent data has the potential to make the task of diagnosis more accurate, it is also 
progressively overwhelming for physicians to adapt. The wide range of studies addressing 
TBN models and applications available in the literature legitimates a formal systematic 
review of TBN applications to medical problems. 
Methods: This systematic review was conducted in accordance with PRISMA 
guidelines. Search was conducted on multiple online databases, including PubMed, ISI 
Web of Knowledge, SCOPUS and DBLP, with no date or study design restrictions. We 
applied standard systematic review methodology for the identification of eligible studies, 
data extraction and assessment of risk of biases. 
Results: From 8761 studies, 42 were deemed eligible for inclusion, and evidence on the 
benefits TBN’s use was obtained. Twenty three (55%) studies addressed DBN as applied 
technique, sixteen (38%) approached the cardiovascular system and 28 (67%) studies were 
derived for prognosis. The analysis showed that the majority of studies found benefits on 
the use of TBN. Significant heterogeneity between was found between studies outcomes 
making it impossible to perform meta-analysis. 
Discussion: This study had the ambition to perform a systematic review, arising novel 
data and content regarding temporal Bayesian network’s application on health-related 
problems. There are a considerable number of published studies that investigate the 
benefits of temporal Bayesian networks applied on health-related problems. These results 
may encourage the use of TBN, given the shown enhanced performance. The resulting 
evidence and/or models might be used in a future development of clinical decision support 
systems. 
Keywords: temporal Bayesian networks; health-related problems; clinical outcomes; 
systematic review. 
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Resumo 
Objetivo: O objetivo deste trabalho foi analisar sistematicamente a literatura sobre 
redes Bayesianas temporais e a sua relação com outcomes clínicos. 
Introdução: O conhecimento médico tem conhecido enorme expansão. Apesar da 
maior facilidade de obtenção de dados pertinentes tornar a tarefa de diagnóstico mais 
eficaz, é também progressivamente mais complexa a adaptação por parte do médico. A 
elevada variedade de estudos sobre redes Bayesianas temporais e as suas aplicações na 
literatura, justifica a realização de uma revisão sistemática relativa à aplicação desta técnica 
na área da saúde. 
Métodos: Esta revisão sistemática foi realizada em concordância com as guidelines do 
PRISMA. A pesquisa foi efetuada em várias bases de dados online, como a PubMed, ISI 
Web of Knowledge, SCOPUS e DBLP, sem restrições de data ou desenho de estudo. Foi 
aplicada metodologia de revisão sistemática padrão para a identificação de estudos 
elegíveis, extração de dados e avaliação do risco de viés. 
Resultados: Em 8761 estudos, 42 foram considerados elegíveis para inclusão, tendo 
sido reunida evidência sobre redes Bayesianas temporais. Vinte e três (55%) estudos 
abordaram redes Bayesianas dinâmicas, dezasseis (38%) versaram o sistema cardiovascular 
e vinte e oito (67%) foram derivados para prognóstico. A análise demonstrou que a maioria 
dos estudos encontrou benefícios no uso de redes Bayesianas temporais. Foi encontrada 
elevada heterogeneidade entre os estudos, impossibilitando a realização de meta-análise. 
Discussão: Este estudo tinha a ambição de realizar uma revisão sistemática, 
descobrindo novos dados e conteúdo sobre redes Bayesianas temporais aplicadas na área da 
saúde. Existe um considerável número de estudos que investigam os benefícios do uso deste 
tipo de redes em problemas relacionados com a saúde. Estes resultados podem incentivar o 
uso de redes Bayesianas temporais, dado o aumento de performance preditiva destas redes. A 
evidência e/ou modelos resultantes podem ser usados no futuro desenvolvimento de sistemas 
de suporte à decisão clínica.  
Palavras-chave: redes bayesianas temporais; problemas na saúde; outcomes clínicos; 
revisão sistemática. 
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Preamble 
As a master’s student with healthcare background, the present study was motivated by 
the constant growing of health-related data and the need to facilitate both the management 
and interpretation of the same. 
That way rises the interest on Temporal Bayesian Networks, which brings a different 
display mode, being capable to deal with multiple factors at multiple time points.  
The conclusion of this study got one year delayed for professional reasons. 
This study was invited for an apresentation at the Annual Symposium of the master’s 
degree in Medical Informatics of the Faculty of Medicine, University of Porto (oral 
presentation on September 23th, 2017). 
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1. Introduction  
Medical knowledge is growing at a fiery rate. While the obtainability of pertinent data 
has the potential to make the task of diagnosis more accurate, it is also progressively 
overwhelming for medical staff to adapt [1]. 
Heijden et al. stated that medical data frequently appears as time series, offering a 
description of the development of a disease over time. Awareness into the evolution of a 
disease is a major aspect of the management of any disease, whether acute or chronic, for 
chronic patients the evolution is even more important, given that the disease will not 
disappear. For chronic diseases it is clinically interesting to study the relation between the 
different variables, approaching signs and symptoms, environmental factors, in terms of 
equally static and temporal relationships [2]. Bayesian networks (BN), introduced in the 
1980s, where implemented to represent and reason with models of problems regarding 
issues like uncertainty, adopting, as a basic framework, the probability theory [3]. 
During the last decade, due to their capability to model complex systems, where such 
relationships between the many variables involved are not entirely known, BN have raised 
much interest in medicine. Also, they offer a causal interpretation instead of merely capture 
association. Given that, they have become popular as prognostic models [4]. BN are 
increasingly used in biomedicine and health-care to support different types of problem 
interpreting, such as diagnostic reasoning, prognostic reasoning, and treatment selection 
and learning functional interactions [5]. 
In a study carried out by Visscher et al. it was found improved performance in the 
prediction of pathogens causing ventilator-associated pneumonia using a BN model [6]. 
According to Young, BN is a strong probabilistic technique of dealing with uncertainty, 
which became popular between artificial intelligence researchers. Nevertheless, one should 
be aware that BN do not directly provide a mechanism to represent temporal dependencies 
[7]. 
In medicine, for many tasks such as prevention, diagnosis, therapeutic management, 
prognosis and discovery, representing and reasoning about time is crucial [8]. According to 
Figueroa, BN are one of the most used techniques for the development of intelligent 
systems, and although BN were not intended to model temporal aspects explicitly, recently 
BN have been applied to reasoning about time under uncertainty [8]. 
Temporal Bayesian Networks (TBN) are temporal extensions of BNs, explicitly 
representing probabilistic relationships between variables, in the form of graphical models. 
Since they have the capability to represent and reason knowledge under uncertainty, TBN 
are highly applicable in the medical field. TBN are particularly important to deal with the 
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explicit or implicit representation of time. That way, they have many applications in 
medicine, like medical diagnosis, forecasting, and medical decision making. Also, they have 
been used in many clinical domains to interpret and reason with several sums of 
longitudinal data [9]. 
According to the literature, there are many types of TBN, although the most popular 
temporal extension of BNs is dynamic Bayesian networks (DBN), which uses a discrete-
time representation. Extensions of DBNs for decision making are dynamic influence 
diagrams (DID) and partially observable Markov decision processes (POMDP). Models 
using interval-based representation of time are: networks of probabilistic events in discrete 
time (NPEDT), modifiable temporal Bayesian networks (mTBN), probabilistic temporal 
networks (PTN) and temporal nodes Bayesian networks (TNBN). Also, models using 
continuous time representation are the continuous time Bayesian networks (CTBN) and 
Berzuini’s network of date’s model. Irregular time Bayesian networks (ITBN) are a new 
temporal extension of BNs which are capable to deal with processes happening irregularly 
through time [9]. 
Temporal probabilistic networks are now being used in many medical problems such as 
diagnosis, treatment selection, therapy monitoring and prognosis. Given their ability to deal 
with uncertainty in time-series medical data they permit one to learn about causal 
relationships and dependencies of clinical features [9]. There are many studies regarding 
TBN models and clinical data. For example, there is evidence of the use of temporal 
reasoning to improve the diagnosis accuracy, on a system called Heart Disease Program 
(HDP) [10]. Charitos et al., with the application of a DBN for the diagnosis of ventilator-
associated pneumonia (VAP) in Intensive Care Unit (ICU) patients, found that 
representing time explicitly and taking into account the patient’s history, rises diagnostic 
performance. In the same study, the DBN shown a better performance at distinguishing 
between VAP and non-VAP patients than the static network [11]. Another example is the 
usage of a DBN model in the diagnosis of apnea [12]. DBN were also used to describe 
changes in organ failures in ICU patients [4]. 
Figueroa also talks about Temporal Bayesian Networks of Events (TBNE) in which 
each node represents an event or state change of a variable, and an arc corresponds to a 
causal-temporal relationship. A temporal node represents the time a variable changes is 
state, including an option of no-change. The temporal intervals can vary in number and 
size for each temporal node, allowing multiple granularity. Temporal information is 
relative, that is, there is not an absolute reference about time. A TBNE creates a formal 
and systematic structure, modelling the temporal evolution of dynamic process [8]. 
Lappenschaar gave an additional contribute developing the concept of Multilevel Temporal 
Bayesian Network (MTBN), with the capability of analyzing multiple outcomes at multiple 
time points [13]. 
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Given the exposed, the wide range of TBN models and applications available in the 
literature, a formal systematic review of TBN applications to medical problems was 
needed. 
The aim of our study was to systematically review the literature on Temporal Bayesian 
Networks (TBN) and its relation with clinical outcomes. Thus, this systematic review will 
answer the following question: 
Are there significant benefits on the use of Temporal Bayesian Networks on health-related 
problems when compared to traditional Bayesian networks or other statistical methods? 
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2. Aim 
The objective of this study, as stated above, was to perform a systematic review of the 
available literature on TBN and its relations with clinical outcomes, attempting to gather 
information about benefits or disadvantages of this technique, when compared to other 
types of techniques.  
For that we defined the following specific objectives: 
 To systematically review the literature on TBN and its relation with clinical outcomes; 
 To identify the benefits of TBN’s application on health-related outcomes; 
 To discover data that might be used in the future development of clinical decision 
support systems.
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3. Material and Methods 
This study is a systematic review that ran from January 2016 to September 2017, with 
the last search being done in February 2016. The methodology of this review is reported 
according to the preferred reporting items for systematic reviews and meta-analyses 
(PRISMA) group[14]. 
3.1. Eligibility criteria 
We aggregated evidence about studies that address TBN and their applicability to health 
research and clinical outcomes. 
3.2. Information sources 
Search was conducted on multiple online databases, including PubMed, ISI Web of 
Knowledge, SCOPUS and DBLP. 
3.3. Search strategy 
There was no study design or date limits on the search. Platforms mentioned above 
were searched using specific queries built with proper keywords and, when relevant, 
classification terms (e.g. MeSH). The proposed query below was adapted for each database: 
((bayes* OR belief OR Bayes Theorem [Mesh] OR causal*) AND (network*)) AND 
(("Longitudinal Studies"[Mesh]) OR "Spatio-Temporal Analysis"[Mesh] OR temporal OR continuous 
OR dynamic* OR longitudinal) 
3.4. Data management 
In this study, all searches were performed independently. All studies were aggregated on 
a specific software, to avoid eventual duplicates. The studies were properly identified, 
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univocally, by a specific identifier. The result of the review process was exported to a data 
analysis software. 
3.5. Selection process  
All studies were independently reviewed by two reviewers, both in the initial phase of 
titles and abstracts, and in the full-text review phase, with the application of the defined 
inclusion criteria. Disagreement was solved through discussion and consensus. 
3.6. Data collection process 
For the application of the eligibility criteria a specific form was used, containing the 
following information. 
 Study ID; 
 Inclusion Criteria: 
o Reference to Temporal Bayesian Networks (the study must approach 
model(s) of Temporal Bayesian Networks); 
o Reference to Health (the study must approach health-related problems). 
Similarly, for the studies’ data extraction, an appropriate form was applied, whose items 
are described in the following area. 
3.7. Data items 
In this review, we have extracted the following data items: 
 Study ID; 
 Type of applied Bayesian network (this section contains the type of Bayesian network 
applied, for instance, Dynamic Bayesian Networks); 
 Compared technique (in this section it was registered the model compared with the 
Bayesian network model, such as multilevel regression); 
 Medical specialty (in this topic it was stated the medical specialty in study, such as 
Cardiology, Neurology, etc); 
 Clinical area (this topic comprised the area of study, such as diagnosis, prognosis, 
therapy, etc);  
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 Modeling goal (this sector approached the purpose of the modelling such as 
improving the diagnosis for a determined pathology); 
 Model evaluation measure (in this section it was evaluated the model’s measures used 
by the authors, such as sensitivity, specificity, the accuracy of a determined prediction, 
etc); 
 Data collection methods (this area approached the data collection methods, such as 
forms); 
 Model validation techniques (this section specified the data model validation 
techniques used by the authors, such as hold-out technique, cross-validation, etc); 
 Cohort description (this topic approached the size of the sample); 
 Development maturity (whether the study reported a model, a pilot study, a prototype 
or a final product); 
 Country; 
 Year. 
3.8. Outcomes  
This review included studies that report the following outcome measures: 
 Model’s applicability; 
 Model’s benefits/advantages comparatively with other techniques; 
 Applications maturation state. 
3.9. Risk of bias assessment 
The risk of bias assessment was conducted in accordance with QUADAS-2[15]. 
3.10. Meta-analysis 
 Since there was high heterogeneity of studies no meta-analysis was conducted regarding 
dealing with missing data, data synthesis, subgroup analysis and investigation of 
heterogeneity or assessment of publication bias. 
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3.11. Ethics approval and consent to participate 
Not applicable.  
3.12. PROSPERO registration 
Although we have tried to register our protocol with PROSPERO, this has been seen as 
not required since “this is a methodology review which has no directly health related outcomes.” 
PROSPERO’s Committee answer follows attached as Annex 1. 
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4. Results 
After applying all of the above criteria, 42 studies were selected, as shown in Figure 1. A 
first impression on the selected papers allowed us to place them in terms of type, time, and 
location while exploring the issues each of them covers.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Study Selection 
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4.1. Descriptive analysis  
We observed that 69% of the articles were originated from Europe, 28% of these were 
originated from Netherlands and 21% of the papers came from the United States of 
America. The great majority of the articles were published between 2012 and 2015 (55%) 
being 2014 the year of bigger contribution with 8 papers. In the field of development 
maturity technology readiness level (TRL) was used. We categorized 15 studies as TRL1 
(36%), 24 studies as TRL2 (57%), 2 as TRL3 (5%) and 1 as TRL4 (2%). Regarding the 
applications maturation state 24 were categorized as needed to be tested (57%) and 18 as 
ready to use (43%). Their main characteristics are summarized in Table 1. 
Risk of bias assessment results are exposed in Table 2. It was possible to find low risk of 
bias in twenty three studies (55%) concerning patient selection; regarding index test, forty 
studies (95%) were considered as of low risk of bias; reference standard risk of bias was 
also assessed with twenty eight studies (66%) founded as unclear for risk of bias with thirty 
four studies (81%) presenting low risk of bias in terms of flow and timing. About 
applicability concerns, in patient selection’s category we found thirty one studies (74%) 
with low risk of introducing bias; concerning index test’s applicability it was possible to 
find thirty nine studies (93%) with low risk; at last the reference standard’s applicability was 
found to have more risk of introducing bias, with twenty eight studies (66%) presenting 
high risk of bias. 
4.1.1. Type of Applied Bayesian Network 
In this section we will expose the different types of BNs applied in the studies. It is 
important to notice that during the study, the most common type of BN was DBN which, 
in this study, is considered a type of TBN. 
Twenty three of forty two studies addressed DBN (55%)[4, 11, 18, 39, 27, 28, 35, 30, 17, 16, 23, 29, 49, 45, 47, 
36, 19, 20, 34, 37, 21, 26, 46]; six of these twenty three studies dedicated their efforts to Cardiovascular 
diseases (CVD), approaching themes like hypertension[18], electrocardiography for 
myocardial infarction classification[39], prediction of coronary atherosclerosis[27, 28], 
prediction of survival in patients with ischaemic heart disease[35] and in patients with 
ventricular assist devices[30]; it was also possible to find six studies addressing different areas 
of Oncology[17, 16, 23, 29, 49, 45]; the Trauma, emergency room and ICU medical specialty was 
found in five out of twenty five studies[4, 47, 36, 19, 20]; the remaining studies varied in their 
medical specialty application, from Pulmonology[11], Diabetes[34, 37], to the category of 
Others, addressing probability of death and spontaneous survival in pediatric acute liver 
failure patients[21], risk of fall from gait[26] and hemodialysis[46]. 
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Study Location Dataset Applied BN Comparison Medical Specialty  Clinical area 
Akutekwe (2014)[16] Europe 16331 features 
(112 patients) 
DBN N.A. Oncology Diagnosis 
Akutekwe (2014)[17] Europe 592 features (72 
patients) 
DBN N.A. Oncology Prognosis 
Akutekwe (2014)[18] Europe 22184 predictor 
genes (159 
patients) 
DBN N.A. CVD Diagnosis 
Almahmoud (2015)[19] North America 472 patients DBN N.A. Trauma Prognosis 
Almahmoud (2015)[20] North America 472 patients DBN N.A. Trauma Prognosis 
Azhar (2013)[21] North America 216 serum 
samples (49 
patients) 
DBN N.A. Others Prognosis 
Ceccon (2011)[22] Europe 62 patients DSBN DBN/BN Ophthalmology Prognosis 
Chang (2008)[23] Germany 231 human breast 
cancer cells 
DBN N.A. Oncology Diagnosis 
Charitos (2009)[11] Europe 157 patients DBN Static network Pulmonology Diagnosis 
Chiang (2010)[24] Asia 905 heartbeats DBN with 
CBFM 
N.A. CVD Diagnosis 
Codecasa (2014)[25] Europe 120 trajectories 
for exercise 
CTBN DBN CVD Prognosis and 
rehabilitation 
Cuaya (2013)[26] North America 66 records (18 
patients) 
DBN N.A. Others Prognosis 
Exarchos (2013)[27] Europe 39 patients DBN N.A. CVD Prognosis 
Exarchos (2015)[28] Europe 39 patients DBN N.A. CVD Prognosis 
Exarchos (2012)[29] Europe 86 patients DBN N.A. Oncology Prognosis 
Exarchos (2014)[30] Europe 71 patients DBN N.A. CVD Prognosis 
Gatti (2012)[31] Europe 3 case studies CTBN DBN CVD Diagnosis and 
prognosis 
Kayaalp (2000)[32] North America 1449 patients STBN NSTBN Trauma Prognosis 
Lappenschaar (2013)[13] Europe 1.5M patients MTBN N.A. CVD Prognosis 
Lappenschaar (2013)[33] Europe 218333 patients MBN MLR CVD Prognosis 
Marini (2015)[34] Europe 1441 patients DBN N.A. Diabetes Prognosis 
Marshall (2010)[35] Europe 2512 patients DBN N.A. CVD Prognosis 
Nachimuthu (2012)[36] North America 3100 patients DBN N.A. Trauma Diagnosis 
Nachimuthu (2010)[37] North America 796 patients DBN Rule-based protocol Diabetes Prognosis 
Olesen (2006)[38] Europe 2414 
questionnaires 
TPSBN BN Others Diagnosis 
Oliveira (2011)[39] South America Not specified DBN BN CVD Diagnosis 
Orphanou (2012)[40]] Europe 176 patients DBN-TA N.A. CVD Prognosis 
Orphanou (2014)[41]  Europe 1428 patients DBN-TA N.A CVD Diagnosis 
Orphanou (2015)[42] Europe Not specified DBN-TA N.A. CVD Diagnosis 
Orphanou (2015)[43] Europe 1417 patients DBN-TA DBN CVD Prognosis 
Peelen (2010)[44] Europe 2271 patients HDBN N.A. Trauma Prognosis 
Peeling (2007)[45] Europe 26+162 patients DBN BN Oncology Diagnosis and 
Prognosis 
Rose (2005)[46] Asia Not specified DBN N.A. Others Prognosis 
Sandri (2014)[4] Europe 79 patients DBN N.A. Trauma Prognosis 
Sebastiani (2005)[47] North America Not specified DBN N.A. Trauma Prognosis 
Tucker (2004)[48] Europe 180+24 patients STBN BN/Linear 
regression/k-nn 
Ophthalmology Diagnosis 
Van der Heijden 
(2014)[2] 
Europe 10 patients TANB/TNB
N 
Aerial/Bootstrap/E
xpert 
Pulmonology Prognosis 
Van Gerven (2008)[49] Europe 3 case studies DBN N.A. Oncology Prognosis 
Verduijn (2007)[50] Europe 10147 patients PBN MDL CVD Prognosis 
Visscher (2007)[51] Europe 2424 patients NRDBM N.A. Pulmonology Prognosis 
Watt (2011)[52] North America 50+4700 patients DBBN LBR-based model Oncology Prognosis 
Watt (2008)[53] North America 4796 patients DBBN Logistic regression Others Prognosis 
Table 1. Characteristics of the included studies 
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Table 2. Risk of bias of the included studies 
(+) = low risk; (-) = high risk; (?) = unclear risk. 
*synthetic dataset 
**no dataset – scenario analysis 
***use of both real and synthetic dataset 
****dataset based on a survey from another survey 
*****compared to other study 
******dataset from cross-section studies 
 
Four of forty two studies approached DBN with temporal abstraction (TA) (9%) in 
order to predict the progression and estimate the risk of coronary heart disease[40, 42, 41, 43]. 
Two of forty two studies (5%) focused on post-stroke rehabilitation[25] and prediction of 
complications and persistence of cardiogenic heart failure[31] using CTBN. It was also 
possible to discover two studies (5%) that applied the concept of Dynamic Bayesian Belief 
networks (DBBN) addressing neuro-oncology[52] and osteoarthritic knee pain[53]. 
Study Risk of Bias Applicability Concerns 
 Patient 
Selection 
Index Test Reference 
Standard 
Flow and Timing Patient 
Selection 
Index Test Reference 
Standard 
Akutekwe (2014)[16] (-) (+) (?) (-) (?) (+) (-) 
Akutekwe (2014)[17] (-) (+) (?) (-) (?) (+) (-) 
Akutekwe (2014)[18] (-) (+) (?) (-) (?) (+) (-) 
Almahmoud (2015)[19] (-) (+) (?) (+) (?) (+) (-) 
Almahmoud (2015)[20] (-) (+) (?) (+) (?) (+) (-) 
Azhar (2013)[21] (+) (+) (?) (-) (+) (+) (-) 
Ceccon (2011)[22] (-) (+) (+) (+) (?) (+) (+) 
Chang (2008)[23] (?*) (+) (?) (+) (?) (+) (-) 
Charitos (2009)[11] (+) (+) (+) (+) (+) (+) (-) 
Chiang (2010)[24] (+) (+) (?) (?) (+) (+) (-) 
Codecasa (2014)[25] (+) (+) (+) (+) (+) (+) (+) 
Cuaya (2013)[26] (+) (+) (?) (+) (+) (+) (-) 
Exarchos (2013)[27] (+) (+) (?) (+) (+) (+) (-) 
Exarchos (2015)[28] (+) (+) (?) (+) (+) (+) (-) 
Exarchos (2012)[29] (+) (+) (?) (+) (+) (+) (-) 
Exarchos (2014)[30] (+) (+) (?) (+) (+) (+) (-) 
Gatti (2012)[31] (?**) (+) (+) (+) (-) (+) (+) 
Kayaalp (2000)[32] (+) (+) (-) (+) (+) (+) (+) 
Lappenschaar (2013)[13] (-) (+) (?) (-) (+) (+) (-) 
Lappenschaar (2013)[33] (?***) (+) (+) (+) (+) (+) (+) 
Marini (2015)[34] (+) (+) (?) (+) (+) (+) (-) 
Marshall (2010)[35] (-) (+) (?) (-) (+) (+) (-) 
Nachimuthu (2012)[36] (+) (+) (?) (+) (+) (+) (-) 
Nachimuthu (2010)[37] (+) (+) (+) (+) (+) (-) (+) 
Olesen (2006)[38] (?****) (+) (?*****) (+) (?****) (+) (?*****) 
Oliveira (2011)[39] (-) (+) (+) (+) (?) (+) (+) 
Orphanou (2012)[40] (+) (+) (?) (+) (+) (-) (-) 
Orphanou (2014)[41]  (+) (+) (?) (+) (+) (+) (-) 
Orphanou (2015)[42] (+) (+) (?) (+) (+) (+) (-) 
Orphanou (2015)[43] (+) (+) (?) (+) (+) (+) (-) 
Peelen (2010)[44] (+) (+) (?) (+) (+) (+) (-) 
Peeling (2007)[45] (?******) (+) (+) (+) (?******) (+) (+) 
Rose (2005)[46] (-) (+) (?) (+) (+) (+) (-) 
Sandri (2014)[4] (+) (+) (?) (+) (+) (-) (-) 
Sebastiani (2005)[47] (+) (+) (?) (-) (+) (+) (-) 
Tucker (2004)[48] (+) (+) (+) (+) (+) (+) (+) 
Van der Heijden 
(2014)[2] 
(-) (+) (+) (+) (+) (+) (+) 
Van Gerven (2008)[49] (-) (+) (?) (+) (+) (+) (-) 
Verduijn (2007)[50] (+) (-) (-) (+) (+) (+) (+) 
Visscher (2007)[51] (-) (+) (?) (+) (+) (+) (-) 
Watt (2011)[52] (-) (+) (+) (+) (+) (+) (+) 
Watt (2008)[53] (+) (-) (-) (+) (+) (+) (+) 
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The remaining eleven studies (26%) approached different types of BNs, such as 
Dynamic Bayesian Network with Constraint-based fuzzy models[24], MTBN[13], Multilevel 
Bayesian Network[33], Prognostic Bayesian Network (PBN)[50], Hierarchical Dynamic 
Bayesian Network[44], Dynamic Stage Bayesian Network (DSBN)[22], Spatiotemporal 
Bayesian Network[48], Stationary Temporal Bayesian Network[32], Non-repetitive Dynamic 
Bayesian Multinetwork[51], TNBN[2] and Tailored Patient Specific Bayesian Network[38]. 
This information is summarized in Table 3: 
 
4.1.2. Medical Specialty 
In this section we will expose the different medical specialties of the studies. 
Sixteen of forty two studies addressed the CVD (38%)[13, 18, 39, 27, 28, 35, 30, 40, 42, 41, 43, 25, 31, 24, 33, 
50]; most of them dedicated their efforts to predict the progression and estimate the risk of 
coronary heart disease[27, 28, 40, 42, 41, 43] while others focused on survival prediction[35] and 
interaction with other diseases[33] of heart failure. Although some of the studies focused on 
disease progression, mortality, multimorbidity, some were derived for diagnosis[18, 39, 42, 41, 24], 
others for prognosis[13, 27, 28, 35, 30, 40, 43, 33, 50], one for both diagnosis and prognosis[31] and one 
for prognosis and rehabilitation[25]. 
Regarding the medical specialty of Oncology we got seven of forty two studies (17%)[17, 
16, 23, 29, 49, 45, 52]. The great majority of these studies approached disease’s prognosis[17, 29, 49, 52], 
while other focused on diagnosis[16, 23] and one of the studies addressed both diagnosis and 
prognosis[45]. 
Concerning the field of Trauma, emergency room and ICU we were able to find seven 
studies (17%)[4, 47, 36, 19, 20, 44, 32]. The great majority of them were derived for disease’s 
prognosis[4, 47, 19, 20, 44, 32], only one addressed diagnosis[36]. 
 DBN DBN with TA Continuous Time BN  DBBN Other type of BN 
M
ed
ic
al
 S
p
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ia
lt
y 
(n
=
4
2
) 
CVD[18, 39, 27, 28, 35, 30] CVD [40, 42, 41, 43] CVD[25, 31] Oncology[52] CVD[13, 24, 33, 50] 
Oncology[17, 16, 23, 29, 49, 45]   Others[53] Trauma, emergency room and ICU[44, 32] 
Trauma, emergency room and 
ICU[4, 47, 36, 19, 20] 
   Pulmonology[2, 51] 
Pulmonology[11]    Ophthalmology[22, 48] 
Diabetes[34, 37]    Others[38] 
Others[21, 26, 46]     
Table 3.  BN distribution by medical specialty 
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In the Pulmonology medical specialty we discovered three articles (6%)[2, 11, 51]. Two of 
them approached the risk of developing ventilator-associated pneumonia[11, 51] and the other 
focused on the prediction of exacerbations in subjects with COPD[2]. 
There were two studies for each of these medical specialties: Ophthalmology (5%)[22, 48] 
and Diabetes (5%)[34, 37]. Three studies were derived for prognosis, addressing visual field 
deterioration in glaucomatous subjects[48], approaching type-1 diabetes complications[34], the 
prediction of serum glucose levels of ICU patients[37]; with one study approaching the 
modelling key stages in the development of glaucoma[22] inserted in the diagnosis category. 
 At last, four articles approaching hemodialysis, knee pain, pediatric acute liver failure 
and risk of fall from gait, categorized as Others (12%), were all derived for prognosis[21, 26, 46, 
53], with only one, regarding immunology that was derived for diagnosis[38]. 
This information is summarized in Table 4: 
 
 
CVD Oncology Trauma/Emergency 
Room/ICU 
Pulmonology Ophthalmology Diabetes Others 
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Prognosis[13, 27, 28, 35, 30, 
40, 43, 33, 50] 
Prognosis[17, 29, 49, 52] Prognosis[4, 47, 19, 20, 44, 32] Prognosis[11, 51] Prognosis[48] Prognosis[34, 37] Prognosis[21, 26, 46, 53] 
Diagnosis[18, 39, 42, 41, 24] Diagnosis[16, 23] Diagnosis[36] Diagnosis[2] Diagnosis[22]  Diagnosis[38] 
Prognosis and 
Diagnosis[31] 
Prognosis and 
Diagnosis[45] 
     
Prognosis and 
Rehabilitation[25] 
      
Table 4.  Medical specialty distribution by clinical area 
4.1.3. Clinical Area 
In this section we will expose the different clinical areas of the studies. 
Twenty eight of forty two studies were derived to prognosis (67%), those studies 
addressed different medical specialties like CVD[13, 27, 28, 35, 30, 40, 43, 33, 50], Oncology[17, 29, 49, 52], 
Trauma, emergency room and ICU[4, 47, 19, 20, 44, 32], Pulmonology[2, 51], Ophthalmology[22], 
Diabetes[34, 37] and the section categorized as Others[21, 26, 46, 53]. 
Regarding the clinical area of diagnosis we got eleven of forty two studies (26%). The 
great majority of these studies addressed cardiovascular system[18, 39, 42, 41, 24], two of eleven 
studies addressed the oncology specialty[16, 23]. The remaining studies were divided in 
medical specialties like Trauma, emergency room and ICU[36], Pulmonology[11], 
Ophthalmology[48] and Others[38]. 
The remaining studies are gathered in the clinical areas of diagnosis and prognosis (5%), 
and prognosis/rehabilitation (2%). diagnosis and prognosis contemplates two studies, one 
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addressing cardiogenic heart failure[31] and another addressing B-cell lymphoma and 
glaucoma[45]. Prognosis/rehabilitation considers a study about post-stroke rehabilitation[25]. 
Table 5 shows the distribution of the clinical areas by the type of applied BN: 
 Prognosis Diagnosis Diagnosis and Prognosis Prognosis and Rehabilitation 
T
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e
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N
 
DBN[4, 27, 28, 35, 30, 17, 29, 49, 47, 
19, 20, 34, 37, 21, 26, 46] 
DBN[11, 18, 39, 16, 23, 36] DBN[45] CTBN[25] 
DBN with TA[40, 43] DBN with TA[42, 41] CTBN[31]  
DBBN[52, 53] Others[24, 48, 38]   
Others[2, 13, 33, 50, 44, 22, 32, 51]    
 Table 5 - Clinical area distribution by BN 
4.2. Applications of Dynamic Bayesian Networks 
This section will point out the results obtained by the twenty five articles addressing 
DBN, splitting each sub-section by medical specialty. 
4.2.1. Cardiovascular Diseases 
In this systematic review it was possible to found six articles regarding both DBN and 
CVD. Exarchos et al. carried out two studies approaching coronary atherosclerosis, in 
order to identify key factors on the progression of the disease. In one of these studies[27] the 
model achieved an overall accuracy of 79%, finding also 5 features that affect more 
prominently the progression of the disease, including diabetes, cholesterol and family 
history of coronary disease; the other study[28] also tried to identify the factors that play a 
key role towards the progression of atherosclerosis, employing these factors in a decision 
support system in order to conjecture about the prognosis of the disease. The results were 
divided in a baseline and a temporal analysis. The temporal analysis outperformed the 
baseline analysis both in sensitivity, specificity and accuracy, for the two major outcomes – 
number of stenosis and atherosclerosis progression. Akutekwe and Seker[18] applied a DBN 
using five feature selection methods, allowing the discovery of possible key biomarkers for 
the diagnosis of hypertension, with least absolute shrinkage and selection operator  
(LASSO) and support vector machine recursive feature (SVM-RFE) linear methods 
showing the best predictive performance. Oliveira et al.[39] performed a comparison 
between a DBN and a BN, regarding the use of a network for the detection of cardiac 
arrhythmias, with the DBN outperforming the BN with an improvement of 6% in terms of 
sensitivity. Marshall et al.[35] tried to establish an association between patient variables, the 
risk of developing CVD and survival, with is main findings being the influence of diastolic 
blood pressure on survival at 5 years follow-up period, also the body mass index (BMI) 
seems to have an impact on survival. Again Exarchos et al.[30] developed a decision support 
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tool to predict the survival probabilities of patients after the implantation of a ventricular 
assist device. Two DBN were developed, a short term and a long term, with both networks 
reaching values of accuracy of 96,97% and 93,55% respectively. 
 
4.2.2. Oncology 
This section will approach the studies where it was possible to find both DBN and 
oncologic diseases. 
Akutekwe and Seker contributed to this area with two studies. One of the studies[17] 
applied four feature selection methods, allowing the discovery of a possible temporal 
association of high quality metabolic features for ovarian cancer, with LASSO showing the 
best predictive accuracy (93%). Two DBN were used to model the temporal relationships 
among 39 features, showing significant relationships among features 219 and 225 and 
between features 534 and 219 through time points. It was also found 20 metabolic 
chemical compounds that can be associated to ovarian cancer. The same authors also 
applied[16] a DBN using feature selection methods, thus allowing the discovery of a possible 
temporal association of high quality biomarker subsets for colorectal cancer diagnosis, but 
it was not possible to found objective outcomes on this study, the same was evaluated in a 
subjective way. Gerven et al.[49] developed a prognostic model and applied it in three low-
grade carcinoid patients taking into account the prediction of the disease evolution, but like 
in the previous study there was no presentation of model evaluation measures. Peeling and 
Tucker[45] approached two datasets (B-cell lymphoma microarray data and glaucoma visual 
field data) using two types of classifiers. Bayesian network classifier (BNC) learnt with no 
temporal information and dynamic bayesian network classifier (DBNC) learnt from pseudo 
time-series, in order to check the relevance of temporal relationships on the classification 
performance. In the b-cell lymphoma dataset, with a ordered dataset on the dataset, the 
DBNC was the best with an improved area under the curve (AUC). Although, a test was 
performed using random ordering and the BNC outperformed the DBNC with sensitivity 
of 0.70 and AUC of 0.84. Regarding the glaucoma dataset, the authors found and 
improvement in the AUC when using the DBNC. In a study carried out by Chang et al.[23] 
it was performed quantitative bayesian inference and model averaging using a set of 
qualitative statements. This approach enabled probabilistic inference by model averaging 
allowing the prediction of probabilistic quantities from a set of qualitative constraints. A 
use case regarding breast cancer is performed, showing realistic quantitative predictions by 
prior knowledge alone, although when additional information about ranges of gene 
expression is taken into account the values get closest to the true values. At last Exarchos 
et al.[29] created a DBN to identify factors that dictate oral squamous cell carcinoma 
progression and to predict potential disease relapses. This study obtained accuracy results 
of 86%, with specificity and sensitivity values of 63,6% and 100% respectively towards 
relapse probability at first follow-up visit . When the authors aggregate baseline analysis 
36  Chapter 4. Results 
____________________________________________________________________ 
 
 
and first follow-up visit towards the prediction of relapse probability at second follow-up 
visit, the results obtained are 100% in sensitivity, specificity and accuracy. Compared with 
previous literature this study has a bigger sample and also greater accuracy values (100%). 
4.2.3. Trauma, emergency room and ICU 
This section will focus on the studies that presented both DBN and Trauma, emergency 
room and ICU related diseases. 
Almahmoud et al, gave their contribute with two studies, in one of the studies[20] the 
authors tried to analyze the impact of prehospital hypotension on systemic acute 
inflammatory response to blunt trauma, using a DBN to infer for inflammatory biomarkers 
within 24 hours post-injury, finding feedback effects of some biomarkers on their own 
productions and showing an effect in the inflammatory response in the hypotensive cohort, 
with the same happening on the normotensive group. The other study of the same 
authors[19] used a DBN to model the evolution of probabilistic dependencies within a 
system over time, in this case to understand the relationship between trauma and 
inflammatory mediators. The DBN findings correlate with those from prior studies, 
addressing the role of different chemokines as central mediators of systemic inflammation 
with a variation on the gravity of the injury. It was also possible to find associations 
between chemokines that is one chemokine level will affect the level of another. Regarding 
the presence of sepsis soon after emergency department arrival, Nachimuthu and Haug[36] 
constructed a DBN with 3,6, 12 and 24 timeslices for each patient. The results presented 
AUC of 0.911, 0.915, 0.937 and 0.944 respectively. It was also possible to found values of 
Sensitivity, Specificity, positive predictive value (PPV), negative predictive value (NPV) and 
F-measure. The respective values increase further as more data becomes available. A study 
performed by Sandri et al.[4]  applied a DBN in order to model sequential organ failure 
assessment (SOFA) score changes in adult critically ill patients, aiming to identify the most 
probable sequence of organ failures in the first week after ICU admission in a three slices 
network. The constructed DBN presented accuracy ranging from 71.62% to 74.95%, that 
when compared to other studies are similar. Additionally, this work showed the existence 
of organ failure sequences more likely to occur than others. At last Sebastiani et al.[47] 
approached the symptoms and mortality of patients with influenza and/or pneumonia 
divided by age in two groups, children and adults. It was found a good performance by the 
DBN. With the children data giving predictive insight to the adult data, influenza like 
illness (ILI) data and of the number of pneumonia or influenza (P&I) deaths. The opposite 
didn’t occur, neither of the other datasets were predictive for the children data. This might 
be explained by the earlier and stronger signals of influenza in children. 
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4.2.4. Pulmonology   
In the Pulmonology medical specialty it was possible to found one article considering 
both DBN and health-related outcomes.  
With Charitos et al.[11]developing a DBN to capture the development of VAP through 
time. The DBN performance was evaluated focusing on the diagnostic prediction per day. 
The overall Brier score (BS) for the DBN was 0.2376, which outperformed the original 
network that had a 0.3370 overall Brier score. The DBN also proved to distinguish better 
between VAP and non-VAP patients. However the original model outperformed the DBN 
when it came to diagnosis patients without VAP. 
4.2.5. Diabetes 
Regarding Diabetes and DBN it’s possible to discover two papers. One of the studies 
was carried out by Marini et al.[34] where the authors attempted to simulate patient health 
state and complications through discretized variables, using two types of models, one 
entirely learned from the data, called data-driven only network (DDO-DBN) and other 
partially driven by literature derived knowledge called expert intervention (EI-DBN). Both 
models were evaluated by state error test and difference between tests (Kolmogorov-
Smirnov). When compared to an edgeless network both models show a very low error for 
the whole period, with less than 10% in error state. When compared with each other they 
don’t differ much, the average error obtained by the DDO-DBN network is only 0.3% 
lower than the one of the EI-DBN network. The other study carried out by Nachimuthu et 
al.[37] developed a DBN model to represent clinical variables and the temporal and 
attemporal relationships underlying insulin and glucose homeostasis. The developed model 
was compared to an existing rule-based protocol (e-Protocol Insulin), showing comparable 
accuracy. In some cases the DBN model recommended lower dosage of insulin, being the 
safer protocol, but the opposite also happened in some ranges of patients. 
4.2.6. Other medical specialties 
This section will contain three studies with each one approaching a different medical 
specialty by use of a DBN. Azhar et al.[21] focused on the development of a DBN in order 
to establish relationships between circulating inflammatory mediators as a function of time 
and pediatric acute liver failure (PALF), in an attempt to identify a possible mechanism of 
the disease. The DBN model allowed to distinguish between cytokines networks associated 
with survival and cytokines networks associated with non-survival. The authors concluded 
that DBN-defined inflammatory networks may be used as new biomarkers for predicting 
outcomes in PALF. Cuaya et al.[26] presented two DBN models to estimate the risk of falls 
in elderly using spatio-temporal gait data and further explore the use of feature selection 
algorithms to automatically choose the gait parameters relevant to predict falls. One model 
was built using gait variables and the other one was constructed using gait variables picked 
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only by feature selection algorithm. Both models showed average precision of 70% in 
predicting both imminent falls and 6 months risk of falling, with some superiority from the 
model built using gait variables with 72.22% for both outcomes. The second model 
achieved 72.22% and 66.66% precision values in predicting both imminent falls and 6 
months risk of falling, respectively. Both models presented good values of specificity and 
sensitivity. At last, Rose et al.[46] carried out a study about a decision support system for 
surveillance of patients suffering from renal failure and treated by hemodialysis. It was 
possible to notice the use of a DBN adapted to the monitoring of the dry weight of 
patients suffering from chronic renal failure treated by hemodialysis. The model was only 
subjective evaluated, with encouraging results according to both nephrologists and patients. 
4.3. Applications of Dynamic Bayesian Networks 
with Temporal Abstraction  
In the present section all studies address the CVD medical’s specialty. 
On this section we will approach the use of DBN with TA in the medical specialty of 
CVD. All of the studies had the same major investigator. In one of these studies Orphanou 
et al.[40] created a DBN with TA incorporation to make predictions for the risk of coronary 
artery disease (CAD) for a specific patient, making only a preliminary approach. In order to 
perform primary coronary heart disease (CHD) risk assessment using the STULONG 
dataset, Orphanou et al.[42] constructed a DBN with TA integration. The model achieved 
satisfactory values of Specificity, Sensitivity, Precision and F1score with 0.73, 0.75, 0.74 and 
0.74 respectively, after clustering oversampling in the dataset. In another study[41] the same 
authors constructed a DBN with TA integration to perform CHD diagnosis on a particular 
patient based on the medical history. The authors divided the dataset in 4 different 
datasets, D1 (original dataset), D2 (defined by random oversampling the minority class), 
D3 (oversampling using synthetic minority oversampling technique for nominal features 
(SMOTE-N)), D4 (combination of oversampling with SMOTE-N and random 
undersampling) and developed four networks, one for each dataset. The worst classified 
dataset was D1 and D4 presented the best classification performance with 91%, 75% and 
82% for Recall, Precision and F1score, respectively. The author also used ROC curves to 
evaluate the models with D4 dataset coming as the best classified. Again, the same authors 
presented[43] an extended DBN model that incorporates TA methods applied to the 
prognosis of the risk of coronary artery disease in the STULONG dataset. Given the 
imbalanced training dataset, the authors divided the dataset in 5 different datasets, D1 
(original dataset), D2 (defined by random oversampling the minority class), D3 
(oversampling using SMOTE-N), D4 (combination of oversampling with SMOTE-N and 
random undersampling) and D5 (oversampling using random oversampling technique and 
clustering undersampling). Then they developed 5 DBN-extended networks, one for each 
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dataset, and 5 DBN networks without TA. In order to evaluate the model’s performance 
the adopted metrics were Precision, Recall and F1score. From both groups of DBN the 
network correspondent to the D5 dataset presented the greatest performance. When 
comparing the DBN-extended network with the DBN network without TA, the first one 
outperformed the last one with 0.72, 0.75 and 0.74 for Precision, Recall and F1score, 
respectively. When it comes to ROC curves, again the DBN-extended network 
outperformed the DBN network without TA, with AUC values of 0.78 and 0.60, 
respectively. 
4.4. Applications of Continuous Time Bayesian 
Networks 
Another variation of DBN are the CTBN which will be addressed in this section, 
regarding the cardiovascular medical specialty.  
There are two studies approaching this technique on this systematic review. One of the 
studies[25] had the goal of analyzing the performance of CTBN classifiers on post-stroke 
rehabilitation. The models presented in the paper have their performance analyzed on both 
synthetic and real datasets. In the synthetic dataset DBN are outperformed by all 
continuous models. The same happens in the real dataset. The other study, carried out by 
Gatti et al.[31] addressed the use of CTBN on the diagnosis of acute cardiogenic heart failure 
while overcoming the main limitations of DBN, referring the interval evidence as a main 
advantage of CTBN when compared to DBN. There are only presented scenarios, making 
the model’s evaluation subjective. 
4.5. Applications of Dynamic Bayesian Belief 
Networks 
The present section will focus on DBBN applied on the medical specialties of Oncology 
and Others. 
In the Oncology field, Watt et al.[52] made use of two datasets, one regarding neuro-
oncology and the other osteoarthritis, to apply two networks - Dynamic Bayesian Belief 
Network (DBBN) and an instant-specific patient model developed using Lazy Bayes Rule 
(LBR). When the performance on the prediction of a disease was compared, in both 
datasets the LBR-based DBBN performs better predictive rates over the regular DBBN. 
On other medical field Watt and Bui[53] constructed a DBBN with the purpose of 
evaluating both static and dynamic BBN-based models performance in the prediction of 
knee osteoarthritis diagnosis and compared them to logistic regression models. According 
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to the authors, the results are encouraging, since both static and dynamic belief networks 
outperformed logistic regression in accuracy for most of variables. 
4.6. Applications of other types of Bayesian 
Networks 
The present section of this systematic review will focus on cardiovascular diseases 
approached by four different Bayesian techniques, such as DBN with Constraint-based 
fuzzy models, PBN, TNBN, Multilevel BN and MTBN which can be distinguished from 
this last one because of its capability of analyzing multiple outcomes at multiple time 
points. 
4.6.1. Cardiovascular Diseases 
Chiang and Hsu[24] presented a combination between DBN and constraint-based fuzzy 
models for myocardial infarction classification with 12-lead ECGs. The proposed classifier 
achieved 86,27% and 78,32% for sensitivity and prediction accuracy respectively. Verduijn 
et al.[50] on the other hand approached the concept of PBN learned from cardiac surgical 
patient’s data, with hospital mortality as main outcome. The PBN was validated in terms of 
calibration and discrimination, with the last one being quantified in terms of ROC curve 
(AUC), and compared to a minimal description length (MDL) network. When comparing 
the discriminative performance of both networks, PBN had a greater performance than 
MDL, with higher AUC values. Both networks got poor results in terms of calibration. 
During the study the authors had some issues on the calibration area which compromised 
the results. Lappenschaar et al.[33] used a multilevel BN to predict interactions between 
heart failure and diabetes mellitus, comparing the results obtained with multilevel 
regression. When the techniques are compared, the multilevel BN obtains AUC values of 
0.90 and 0.84 for diabetes mellitus and heart failure respectively; and the multilevel 
regression (MLR) model obtains AUC values of 0.89 and 0.83 for the same outcomes. 
With a model similar to this last one, the same major investigator et al.[13] addressed the 
course of multimorbidity adopting MTBN, investigating the simultaneous progression of 
six chronic cardiovascular conditions. It was possible to establish associations between 
comorbidities and risk of cardiovascular disease progression both in quantitative and 
qualitative analysis, with a novel way of visualization. 
4.6.2. Trauma, emergency room and ICU 
In the Trauma, emergency room and ICU category, was possible to found two different 
types of models, a Hierarchical DBN and a comparison between stationary and non-
stationary temporal BN. The first one was proposed by Peelen et al.[44] a hierarchical DBN 
in order to identify temporal patterns, predict future course of disease and test clinical 
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hypotheses regarding patients in an ICU. Also the models should be able to consider 
dynamics of organ failure at the ICU on two levels: processes regarding an eventual stay at 
the ICU and the processes related to development or persistence of organ failure in 
successive days on ICU environment. The model is applied on a case-study of patients 
admitted to the ICU with severe sepsis. Three Markov models were developed related to 
clinical outcome hypotheses written in the literature: Model I (severity of organ failure over 
time), Model II (failure on specific organs), Model III (extension of Model II, 
distinguishing between persistent organ failure and new organ failure). For all models, the 
patient can only present three states: patient at the ICU, patient has died, patient has been 
discharged from the ICU. Since Model I has only one category with seven possible values, 
it remained as a DBN, while Model II and III became hierarchical DBN. The first model 
showed an association between organ failure severity and death at ICU in the first 3 days, 
also finding that after one week the severity-of-illness is no longer significant for the 
patient’s state at the next day. The second model, comparing to the first one, has the 
capability of being more specific, since it can distinguish between different organs, which 
one has a biggest impact on ICU stay or discharge. Model III has shown associations 
between certain organ failures persistence, with some organs contributing for a certain 
organ failure, but not being associated with its development. All models were evaluated in 
terms of error rate, AUC and discriminatory performance with all achieving similar results. 
On the other hand, as stated above, Kayaalp et al.[32] induced a stationary and 33 non-
stationary temporal models from the same dataset, comparing the difference in the 
predictive performance of the models, in order to model efficiency of both types of models 
and mortality prediction in ICU. AUC for the stationary model was 0.83 and 0.74 for all 
the non-stationary models. It was possible to see that when the model gets larger it decays 
its performance. According to the authors, the study proved that non-stationary models 
can perform as well or even better than stationary models. 
4.6.3. Pulmonology 
With the attempt of temporal analyze data of patients in ICU who either have VAP or 
VAP for short, or ICU patients without VAP, Visscher et al.[51] used a Non-repetitive BN, 
creating three models. However the results from each model were not compared and the 
gathered information was used to find associations between variables, with no significant 
results achieved. On another study, Heijden et al.[2] developed predictive models to evaluate 
chronic obstructive pulmonary disease (COPD) patient’s health, in an attempt to facilitate 
these patients self-management in a home-care setting. After performing an receiver 
operating characteristic (ROC) analysis all models shown AUC of 0.63. When the TNBN 
was tested it achieved values of 0.80, 0.75 and 0.24 for AUC, true positive rate (TPR) and 
false positive rate (FPR) respectively, showing worst performance than the other models, 
such as temporal augmented naïve bayes (TANB), Aerial and Bootstrap, which, according 
to the authors, can be explained by limited data that worsens the performance of the 
network. 
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4.6.4. Ophthalmology 
The Ophthalmology medical specialty, more specifically glaucoma, was addressed by 
Ceccon et al.[22] using a DSBN to efficiently remove noisy data points and identify and 
model the key stages in a temporal process, attempting to obtain better performance in 
classification when compared with both a static and a dynamic BN. The DSBN (AUC – 
0.83) outperformed both the BN (AUC – 0.77) and the DBN (AUC – 0.73) performance, 
also after cross validation, obtaining better accuracy values. With the intent of analyzing 
classification models to predict whether a certain patient has glaucoma or not. Tucker et 
al.[48] developed a Spatio-temporal BN classifier, which outperformed the other BN 
classifiers with a AUC of 0.88. When compared with linear regression and k-nn, the model 
gets similar to those, but still worst. According to the authors in addition to the good 
performance, the proposed model has the capability of making explicit all relationships in 
the network structure and allows to incorporate temporal aspect of the data in a model, 
combining different types of data. 
4.7. Other medical specialties 
In an attempt to calculate the probability of Lyme disease on a specific patient, given its 
clinical history, Olesen et al.[38] developed a BN that incorporates the full clinical history of 
individual patients. According to the authors when compared to other study the proposed 
model achieved higher probability of Lyme disease.  

44  Chapter 5. Discussion 
____________________________________________________________________ 
 
5. Discussion 
The application of BN in the health-related problems experienced considerable growth 
and expansion in the last decades. Besides the existence of substantial research regarding 
the benefits of the implementation and use of the above mentioned techniques on 
healthcare area, the available evidence is not much specific when it comes to outcomes 
exploration, conditioning the conclusions retrieved.  
Since the beginning of this systematic review it was our aim to arise novel data and 
content regarding TBN’s application on health-related problems, offering information 
valuable to the clinical area, strengthening the clinical decision support systems. That way, 
and given the heterogeneity of our results it is of great value the assessment of patterns 
regarding the benefits and challenges with TBN’s implementations. 
This study comprised a total of 42 studies from different countries, regarding different 
studies designs (including descriptive and analytic studies). Carrying different 
methodological approaches to have an enhanced understanding of the impact and benefits 
of using these kind of techniques on healthcare data.  
As stated above, it was found considerable heterogeneity in the outcomes assessed, as 
well as in the applied techniques in the studies. Furthermore some studies focused only on 
a subjective evaluation, turning their assessment less accurate. For this purpose, the results 
were organized by type of TBN divided by the respective medical specialties of application. 
In spite of the variability of the assessed outcomes, our analysis shows common 
evidence on the use of TBN.  
The most commonly found type of BN during this systematic review was DBN, 
comprising 55% of the studies’ total. This particular technique was used with many 
objectives such as: discover features affecting more prominently the progression of 
coronary atherosclerosis[27] (like diabetes, cholesterol, family history of coronary disease, 
among others); identify key role factors towards the progression of atherosclerosis[28]; 
discover of possible key biomarkers for the diagnosis of hypertension[18]; detection of 
cardiac arrhythmias[39]; association between patient variables, risk of developing CVD and 
survival[35]; survival’s prediction after ventricular assist device implantation[30]; discovery of 
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possible temporal association of high quality metabolic features for ovarian cancer[17] and 
colorectal cancer[16] diagnosis; identify factors that dictate oral squamous cell carcinoma 
progression and to predict potential disease relapses[29]; analyze the impact of prehospital 
hypotension on systemic acute inflammatory response to blunt trauma[20]; find associations 
between trauma and inflammatory mediators[19]; model sequential organ failure in adult 
critically ill patients[4]; capture VAP progression through time[11]; represent clinical variables 
and the temporal and atemporal relationships underlying insulin and glucose 
homeostasis[37]; establish relationships between circulating inflammatory mediators and 
PALF[21]; estimate the risk of fall in elderly[26]; surveillance of patients suffering from renal 
failure and treated by hemodialysis[46].  
For the great majority of these studies it was possible to extract increased value. For 
example, in the study[21] aiming to establish relationships between circulating inflammatory 
mediators and PALF, the authors concluded that the network may be used as new 
biomarkers for predicting outcomes in PALF. Another example is the study[4] that tried to 
model sequential organ failure in adult critically ill patients, where the according to the 
authors the study showed the existence of organ failure sequences more likely to occur 
than others.  
Regarding the network’s performance it is important to apprise that some studies didn’t 
assessed objective outcomes. In the ones that applied model’s evaluation measurements, it 
is possible to highlight an improvement of 6% in sensitivity on the study approaching 
detection of cardiac arrhythmias[39]; the study addressing survival’s prediction after 
ventricular assist device implantation reached accuracy values of 96,67% and 93,55% for 
the two developed DBN[30]; also the study whose aim was to identify factors that dictate 
oral squamous cell carcinoma progression and to predict potential disease relapses when 
baseline analysis and first follow-up visit were aggregated towards prediction of relapse 
probability at second follow-up visit obtained values of 100% in sensitivity, specificity and 
accuracy, which compared to previous literature shows greater accuracy values in a bigger 
sample[29]. 
Concerning DBN with TA, this type of network was modeled for three different 
objectives, within the medical specialty of CVD, risk assessment[42], diagnosis[41] and 
prognosis[43] of CAD. Regarding performance, in all studies which the models were 
evaluated, the DBN with TA outperformed regular DBN for all values, such as sensitivity, 
specificity, F1score and precision.  
Relating to CTBN, it was possible to find model’s evaluation in one of the studies with 
the performance result being favorable for CTBN comparing to DBN, in the study of 
post-stroke rehabilitation[25].  
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About DBBN, favorable performance was found in knee osteoarthritis diagnosis with 
both static and dynamic belief networks outperforming logistic regression in accuracy for 
most of variables[53]. 
Addressing other types of BN it’s important to highlight a MBN applied to predict 
interactions between heart failure and diabetes mellitus, comparing the results obtained 
with MLR, in which MBN slightly outperformed MLR in AUC values, for both heart 
failure and diabetes[33]. In another study worth noting was applied a MTBN, addressing the 
course of multimorbidity, considering the simultaneous progression of six chronic 
cardiovascular conditions, where it was found associations between comorbidities and risk 
of CVD progression[13]. In the Trauma, emergency room and ICU medical specialty it is 
essential to point a study that applied a hierarchical DBN in the endeavor of predicting a 
disease’s course in ICU patients, in which the proposed model outperformed DBN, and 
additionally it showed that some organs contribute for a certain organ failure persistence 
and, also, it was able to distinguish the impact of different organs on ICU stay or 
discharge[44]. 
In summary, this systematic review showed the potential of TBN’s use on clinical 
decision support systems by carrying value on both performance and associations 
establishments. Addressing performance, it is possible to indicate the superiority of BN 
containing temporal integration when compared to static BN or other types of techniques 
in the great majority of studies. It was also possible to stablish important temporal 
associations between key biomarkers and the progression, risk assessment or diagnosis of 
some diseases, like hypertension, atherosclerosis, ovarian cancer, systemic inflammation, 
sepsis, among others.  
The resulting evidence unravels information about the large number of techniques 
derived from BN, which might be used in a future development of clinical decision support 
systems. 
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6. Concluding remarks 
From the developed work we identified several findings and can now propose some 
recommendations. 
6.1. Main findings 
It is possible to highlight the following main findings: 
 The found evidence showed the benefit of adding temporal information to Bayesian 
networks, both in performance and in the discovery of new associations between 
variables; 
 Although the large number of papers published addressing Bayesian networks it was 
possible to find a  lack of application of  temporal Bayesian networks on health-related 
problems; 
 In this study it was discovered a sheer number of types of networks developed in the 
last years. 
6.2. Main recommendations 
As main recommendations it is possible to propose: 
 The use of temporal Bayesian networks applied to health-related problems could stand 
as a relevant contribute; 
 It would be of great relevance the use of more standardized Bayesian network models; 
 The use of more homogeneous model’s evaluation measures is essential in order to 
assess the evidence of state of the art methods. 
As future work, the application of temporal Bayesian networks in the field of 
Inflammatory Bowel Disease and Myocardial Infarction is already under development. 
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